SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
In today’s fast-paced business environment, efficient and accurate financial reporting is crucial for making informed decisions. Manually consolidating and transforming financial data from multiple ...
Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results